Immunomodulator Clarithromycin Enhances Mucosal and Systemic Immune Responses and Reduces Re-Infection Rate in Pediatric Patients with Influenza Treated with Antiviral Neuraminidase Inhibitors: A Retrospective Analysis
Open Access
- 17 July 2013
- journal article
- research article
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 8 (7), e70060
- https://doi.org/10.1371/journal.pone.0070060
Abstract
Treatment with antiviral neuraminidase inhibitors suppresses influenza viral replication and antigen production, resulting in marked attenuation of mucosal immunity and mild suppression of systemic immunity in mice. This study investigated the effects of immunomodulator clarithromycin (CAM) supplementation on mucosal and systemic immunity in pediatric patients with influenza treated with neuraminidase inhibitors. A retrospective, non-randomized case series study was conducted among five treatment groups of 195 children aged 5.9±3.3 years infected with influenza A in 2008/2009 season. The five treatment groups were oseltamivir (OSV), zanamivir (ZNV), OSV+CAM, ZNV+CAM and untreated groups. Anti-viral secretory IgA (S-IgA) levels in nasal washes and IgG levels in sera were measured. The re-infection rate was analyzed among the same five treatment groups in the 2009/2010 season. Treatment of influenza with OSV and ZNV for 5 days attenuated the induction of anti-viral S-IgA in nasal washes and anti-viral IgG in serum, compared with the untreated group. The combination of CAM plus OSV or ZNV boosted and restored the production of mucosal S-IgA and systemic IgG. The re-infection rates in the subsequent season were significantly higher in the OSV and ZNV groups than the untreated, while CAM+OSV and CAM+ZNV tended to reduce such rate. CAM restored the attenuated anti-viral mucosal and systemic immunity and reduced the re-infection rate in the subsequent year in pediatric patients with influenza treated with OSV and ZNV.Keywords
This publication has 25 references indexed in Scilit:
- Oral Clarithromycin Enhances Airway Immunoglobulin A (IgA) Immunity through Induction of IgA Class Switching Recombination and B-Cell-Activating Factor of the Tumor Necrosis Factor Family Molecule on Mucosal Dendritic Cells in Mice Infected with Influenza A VirusJournal of Virology, 2012
- Attenuation of inducible respiratory immune responses by oseltamivir treatment in mice infected with influenza A virusMicrobes and Infection, 2010
- Boost of mucosal secretory immunoglobulin A response by clarithromycin in paediatric influenzaRespirology, 2009
- Influenza vaccine with Surfacten, a modified pulmonary surfactant, induces systemic and mucosal immune responses without side effects in minipigsVaccine, 2009
- Clarithromycin in the treatment of RSV bronchiolitis: a double-blind, randomised, placebo-controlled trialEuropean Respiratory Journal, 2006
- Plasma-cell homingNature Reviews Immunology, 2003
- Clarithromycin Inhibits NF-κB Activation in Human Peripheral Blood Mononuclear Cells and Pulmonary Epithelial CellsAntimicrobial Agents and Chemotherapy, 2001
- Anti-inflammatory activity of macrolides: a new therapeutic potential?Journal of Antimicrobial Chemotherapy, 1998
- The Systemic and Mucosal Immune Response of Humans to Influenza A VirusPublished by Springer Science and Business Media LLC ,1989
- Cross‐protection in mice infected with influenza A virus by the respiratory route is correlated with local IgA antibody rather than serum antibody or cytotoxic T cell reactivityEuropean Journal of Immunology, 1984